Exploring the Effect of COVID-19 on HTA Bodies Now and in the Future
Chair: Matthew Brougham, Senior Global Consultant, Certara Evidence and Access
Iñaki Gutiérrez Ibarluzea, President, HTAi and Director of Innovation, Basque Foundation for Health Innovation and Research (BIOEF)
Michelle Mujoomdar, Director, Scientific Affairs, Canadian Agency for Drugs and Technologies in Health (CADTH)
Lou Garrison, Professor, Departments of Pharmacy, Global Health and Health Services, University of Washington
Date: July 14, 2020
Time: 11:00 am ET
Duration: 1 hour
The COVID-19 pandemic has turned our lives upside down and so many questions remain, including around how it is affecting health technology assessment (HTA) bodies. HTA bodies report that they have had to ramp up and are increasingly relying on smaller evidence sets. Going forward the priorities for and speed of assessments, particularly for vaccines, is likely to increase. On top of this, economies struggling with significantly increased levels of debt may respond by tightening budgets outside communicable diseases thus affecting assessment priorities, methods and recommendations.
During this panel, we will explore how the pandemic is affecting HTA bodies in Europe and NA now and how it might affect them and their processes in the future. We’ve invited HTA and pharmaceutical market experts to provide their insights on the following questions:
- How are HTA bodies around the world responding to the COVID-19 pandemic?
- Is there any early evidence of changes to process and priorities? If so, what are they?
- How are processes and priorities likely to change moving forward?
- Will tighter budgets, should they arise, change process, priorities, and assessments?
- What other impacts might this pandemic have on the pharmaceutical industry?
- Will some therapeutic areas be more affected than others?
- Might HTA body assessment processes weight impacts of new health technologies differently?
- Will the COVID-19 pandemic experience have any impact more broadly on societal preferences/decision-making weights and, thus, resource allocation decisions?
- Should the COVID-19 pandemic have an impact on HTA process and/or societal preferences?